Find the source for the question
These studies and FDA pages have different jobs. Each note explains the question a source helps answer. For the full discussion, open the relevant compound page. For the details, follow the source itself.
A useful source answers a particular question.
Identity and regulatory limits
- FDA’s compounding safety concerns
- Here FDA lists withdrawn nominations alongside ongoing safety concerns. The content date reads April 22, 2026; withdrawal offers no clearance.
- FDA’s BPC-157 review
- FDA examines BPC-157 names, chemical forms and test certificates, including gaps a purity figure leaves open.
- FDA’s unapproved GLP-1 drug concerns
- This FDA page explains the federal prohibition on compounding retatrutide. No use has FDA approval.
The regulatory answer cannot be borrowed from a chemical test.
BPC-157 in people and before people
- BPC-157 musculoskeletal evidence review
- This review contrasts promising animal work with very little human evidence and a lack of large trials.
- BPC-157 intravenous safety pilot
- The two participants had both tried intravenous BPC-157 before this study. Its authors reported no adverse effects, without testing injury healing or establishing safety for new users.
- BPC-157 blood-vessel signalling experiments
- Cell and animal experiments explored blood-vessel growth. They did not establish injury recovery in people.
A mechanism and a clinical benefit are different findings.
GHK preparations and delivery
- Review of topical GHK and formulation
- This review covers topical GHK, stability and getting it through skin: questions about the finished preparation.
- Study of a GHK combination on the scalp
- Men with pattern hair loss received GHK without copper, mixed with another ingredient. It wasn’t injected GHK-Cu.
- Copper movement through skin outside the body
- This lab experiment tracked copper through separate skin layers. Cosmetic improvement in living people wasn’t measured.
- FDA’s GHK-Cu compounding categories
- Non-injectable GHK-Cu appears in Category 1 on this list dated May 14, 2026. FDA generally intends not to take enforcement action under its interim policy’s conditions; this is not approval.
- FDA’s explanation of cosmetics rules
- FDA explains how a skin product’s intended use decides whether it follows cosmetic or drug rules.
The whole preparation belongs in the description.
Metabolic medicines in their study settings
- Retatrutide phase 2 obesity trial
- This phase 2 obesity trial measured weight change and reported stomach effects and increased heart rate.
- Retatrutide’s three receptor interactions
- Lab work examines how one retatrutide molecule interacts with three hormone targets. It does not verify another sample.
- Retatrutide phase 2 diabetes trial
- This separate phase 2 trial studied retatrutide in people with type 2 diabetes, measuring blood sugar and weight.
- Tirzepatide obesity trial
- A trial in adults without diabetes compared tirzepatide with a dummy treatment and found greater average weight loss.
- Zepbound prescribing information for tirzepatide
- The Zepbound label describes the approved tirzepatide medicine and its warnings. Compounded versions are not FDA-approved.
I keep each result with the study or product it describes.